New Technology Developed for Detecting TBI Biomarker

Researchers from the NYU Langone Medical Center have introduced new technology that could help advance blood biomarker capabilities, which show changes in low concentration of specific proteins that are present following a neurological injury. The single-molecule array technology offers unprecendented improvements in protein sensitivity over current technologies for the detection of blood-based biomarkers. The new technology allows for more effective measurement of low concentration of proteins — such as tau. Utilizing this technology, researchers hope to develop and validate a simple, more objective blood biomarker for the diagnosis, prognosis and treatment of traumatic brain injury (TBI). Until recently, there have been limits in tissue availability and technology that can help detect specific proteins and other potential biomarkers in the blood following TBI. The results of the study show that a large number of people whose brains appear normal on standard imaging tests could actually have some form of injury, whose course is not well understood. “This presents a unique opportunity to develop a mechanisms-based classification of TBI in the context of personalized medicine,” said a scientific advisor. To read more about this technology, click here.